I see the future and the future is bright indeed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everyone needs to read this report from Fudamental Research on $ISOLF this is very positive to say the least. It came out yesterday late afternoon.
Here's the Link below.
http://bit.ly/2paPCeA
ISOL ISODIOL INTERNATIONAL INC
Isodiol International Inc. (CSE: ISOL / OTCQB: ISOLF) (Frankfurt: LB6A) – Initiating; Leading Cannabis/CBD Company Expanding Rapidly
Cannabis
Fundamental Research just did a 20 Page write up on $ISOLF.
http://bit.ly/2paPCeA
$ISOLF
More $ISOLF News out, they closed on the PP.
ORIGINAL: Isodiol International Inc. Closes First Tranche of Strategic Financing
2017-12-21 13:03 ET - News Release
VANCOUVER, British Columbia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that, further to its news release dated December 19, 2017, the Company has closed the first tranche of its non-brokered private placement (the "Offering") for $20,000,000 CAD by issuing 16,000,000 units ("Units") at a price of $1.25 per unit.
“With this capital, we now have the utmost flexibility to continue our aggressive pursuits of global expansion, as well as the ability to pursue additional strategic acquisitions,” said Marcos Agramont, CEO of Isodiol. "Overall, this capital will be critical in achieving our vision of becoming the global leader in providing pharmaceutical grade phytoceuticals and as we head into 2018, we will continue to be relentless in our efforts to grow and expand our business.”
The Company anticipates the second tranche to be closed by Friday, December 22, 2017.
With respect to the Offering, each Unit will comprise one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $2.00 for a period of twenty-four (24) months from the closing of the Offering.
The securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance pursuant to applicable securities laws. The Company has paid certain eligible persons (the "Finders") a cash commission equal to 6% of the proceeds raised from subscribers introduced to the Offering by such Finders and also issued broker warrants (the “Broker Warrants”) equal to 6% of the securities purchased by such subscribers.
For more information on Isodiol, please visit www.isodiol.com.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2549580&symbol=ISOL®ion=C
Here's an Interview that just went out on $ISOLF. Overall I think it sounds like 2018 is going to be very Positive Imho.
The development of cannabis as a plant medicine has exploded in recent years, with particular focus on the cannabinoid cannabidiol (CBD). CBD has been found to help treat a myriad of issues and ailments, including pain, insomnia, anxiety, stress, and migraines, just to name a few. Isodiol (CSE: ISOL) ( OTC: ISOLF) (FSE: LB6A.F) is the global leader in the advancement of cannabinoid-derived bioactive phytoceuticals, with products available in a variety of countries around the world. The company recently announced the acquisition of the rights to become the exclusive worldwide distributor of Advanced Brain Monitoring’s (ABM) Electroencephalogram (EEG) technology.
CFN Media sat down with Isodiol Chairman of the Board Aman Parmar and Director of Communications Christopher Hussey to discuss the company’s advanced R&D and how they are disrupting the CBD market – and international health as well.
Rachelle Gordon: What is the history of Isodiol?
Christopher Hussey: Isodiol International was founded in 2009 by a gentleman named Jared Berry. I know this sounds cliché, but our goal from the beginning has been to change the world through helping people live better; you will hear that in our office every single day. We are very passionate about plants, and what plants have to offer to the medicinal and the wellness community.
And so, we create both pharmaceutical and nutraceutical products, depending on the continent. Politics and legality is different in every state and country. And so, at this time, we have nutraceuticals in multiple countries and also have pharmaceuticals in some countries and we are working towards more pharmaceuticals on more continents.
RG: Tell us about your path to going public?
Aman Parmar: Prior to going public, we did two rounds of financing in late 2016, and then we did another round in February of this year, for a total of about $3 million dollars.
Then on the actual RTO round in May, we did $4.1 million dollars, which was at 12 cents. Since then, we’ve done subsequent rounds of financing at 25 and most recently, a few weeks ago, we closed a $9 million dollar round at 74 cents.
We’ve had a good movement in the stock over the last few weeks, which we can attribute to some of the major announcements we’ve put out around our hops-derived CBD, acquisitions, and some of the technologies that we have in-licensed into our portfolio. It’s been good for our investors this year as far as a returning stock goes.
RG: Isodiol sells to both large-scale operations and direct to consumers. How you benefit from both of those groups?
AP: Isodiol has the ability to partner or work with multiple verticals of people. For instance, if you’re a distributor who is creating products, or if you’re a distributor who is selling to that end user, we have raw materials on multiple levels that we can shop to that distributor.
In addition, we have an affiliate program on all of our products, a direct-to-consumer affiliate program, and we also sell our products direct-to-consumer from the house. In addition to those three, we also white label.
RG: How did Isodiol develop their new hops-derived CBD?
CH: The industry right now believes in this statement, “Cannabinoids come from cannabis.” Now, while that statement is true, it is also not true. The correct statement is, “Cannabinoids come from cannabis as well as other plants.” The industry currently has grown based on one plant and if you’re inside the industry, you’ll know there are several challenges from the political landscape, the legal landscape and also, a supply and demand landscape, depending on where you are. So imagine a future where there are multiple plants where you can derive CBD as well as terpenes as well as caryophyllene, humulene – all of the different endocannabinoids and cannabinoids, and all the different supplemental molecules.
We know, as an educated scientific community, that essential oils have some of the same properties as cannabinoids, and have some of the same properties as basil or lavender. They share multiple properties. The same is true with the cannabaceae family of plants as well as other families of plants. We’ve partnered with the right scientists and communities and we’ve introduced the very first non-cannabis CBD.
RG: How do you think that these discoveries in R&D will affect growth?
CH: There’s no place in the world where hops are illegal. So, you woke up on Monday morning and now your product suite was available to the entire population. How would that change your business? How would that change your bottom line? How would that change your possibilities?
The reality of that story is it changes the conversation. Is hops-based CBD going to change the legality in the United States? We don’t know but we’ve started the conversation. Are we going to discover other plants that make it viable? Is this going to explode the market from the $55 billion it’s going to be here in a few years? Probably. We’ve opened up entirely new marketplaces because hops isn’t illegal anywhere. Liverwort isn’t illegal anywhere. Flax seed isn’t illegal anywhere. It’s an entirely new domain and an entirely new market.
RG: What are your projections for growth?
AP: I think when you look at our market in the US, you’ll see consistent growth month over month, between $1.3 and $1.5 million in revenue. As we approach the international market and start building up Latin American and European market, I think those numbers will start to grow quite significantly.
Heading into January 2018, our revenue is increasing from $1.5 to about $2 million a month, and as we head to the back half of 2018, our projections show that we’ll be in the $2.5 to $3 million range per month in revenue.
Our profitability is one of the most important things in the sector. We are consistently running at about 18 to 22 percent dividend on our revenue, so we are profitable. Over the last few weeks we’ve had some acquisitions around the US. All these brands will be managed in their own division, and again, our running revenues are profitable within their own operations. I see revenues ramping up in 2018 on the international front, toward the back half of the year.
RG: Tell us about the recent acquisition of Be Tru Organics?
AP: They’re based out of California, and have been in operations for about a year now. It was a great acquisition for us. Keith Gordon, the CEO, has been in sales and distribution for well over 25 years, and is a really strong addition to our management team. We’ve done a real good job at infiltrating some of the more common distribution challenges in the US, and that’s all stuff that we are implementing in the market.
Be Tru will find some national distribution and what they do is they’ve branded all of their products as hemp oil, so they’ve been able to get some mainstream distribution from just branding it a bit differently than most people in this space.
RG: Why should potential investors look at Isodiol and what exposure does the company provide?
AP: Over the last six months, we’ve really focused on developing the science IP behind the products. We’ll focus on building revenues and really getting our products out there, but what differentiates us from everybody else is the science and the actually ability for us to prove out why the compound is beneficial for the human body.
I think as we push into 2018 and we start working on some of the clinical trials, and we start seeing some of the acquisitions that have happened over in the UK, I think the market and investors will see that we are truly different in that we’re investing into developing an IP portfolio that was second to none.
We’ll start seeing a lot more celebrations with mainstream universities, colleges, and professionals in helping validate that science. Developing technologies like the non-cannabis derivative CBD has been an absolute momentous announcement for us. You’ll see a lot more of that as we head into 2018.
An overall picture of Isodiol is it’s just a family of brands. We’ve done an incredible job with building up that portfolio of products that we hit different distribution channels of those in the US, Canada, and internationally. We’ve got exciting things in the pipeline that will benefit the consumer and the shareholder, you’ll see that story really start to develop within the next year.
$ISOLF News just out.
ORIGINAL: Isodiol International Inc. Announces Strategic $30,000,000 CAD Financing
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2548535&symbol=ISOL®ion=C
Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has entered into a binding agreement to acquire the Biosynthesis Pharma Group (BSPG), an industry leading producer of industrial hemp, it's derivatives and pharmaceutical compounds for use in the medicinal, nutraceutical, food and cosmetic industries.
Through BSPG's industrial-sized, proprietary extraction methodologies, BSPG produces high-purity, bioactive cannabinoids that are used in pharmaceutical applications to benefit those suffering from a range of life-threatening and non-life-threatening illnesses. BSPG is currently conducting clinical trials involving its product through strategic partnerships around the globe.
"It has been a part of Isodiol's growth strategy to aggressively pursue international expansion. Through this acquisition, the company is aligned to penetrate foreign markets particularly in the United Kingdom, Europe, Asia, South and Central America. We will broaden our product availability and make the most bioactive cannabinoid products available on a global scale. This acquisition puts us at the forefront of global cannabinoid clinical research and studies which will compliment our current efforts in Brazil and other markets we are presently developing," said Marcos Agramont, CEO of Isodiol.
The BSPG acquisition includes multiple entities that are strategic to the future of Isodiol. Each of these entities are intended to have a distinct purpose within the Isodiol organization, whether it be defined by geography, applicable laws, or line of business. The entities include:
-- Biosynthesis Pharma Group Limited (BSPG-HK): organized in Hong Kong and maintains a correspondent office in the United Kingdom. Isodiol is acquiring 100% of BSPG-HK.
-- Trigal Pharma GmbH (TP-Austria): organized in Austria, TP-Austria's business includes, but is not limited to, the handling of regulatory and governmental policies and supply of pharmaceutical-grade CBD to pharmacies in Europe. Isodiol is acquiring 100% of TP-Austria.
-- Hankang (Yunnan) Biotech Co., Ltd. (HBTC-China): organized in The People's Republic of China, HBTC-China's business includes, but is not limited to, operating a facility approved by the Chinese government to grow hemp as well as extract and export CBD globally. China is the world's largest producer of hemp and is the largest supplier of raw hemp and fiber to the United States. Isodiol is acquiring 70% of HBTC-China.
-- BSPG Laboratories Limited (BSPGL-UK): organized in the United Kingdom, BSPGL-UK's business includes, but is not limited to, operating a facility that refines the CBD molecule to a purity of 99.5% + that is pharmaceutical-grade, THC-Free and highly bioactive. Isodiol is acquiring 100% of BSPGL-UK.
-- Pure CBD Limited (PURE-UK): organized in the United Kingdom, PURE-UK supplies pharmaceutical products under the specials category with the approval of the National Health Service. Isodiol is acquiring 100% of PURE-UK.
-- Purodiol Limited (PUR-UK): organized in the United Kingdom, PUR-UK manufactures pharmaceutical products under the brand name Purodiol. Isodiol is acquiring 100% of PUR-UK.
-- Purodiol Do Brasil Ltda (PUR-Brazil): organized in Brazil, PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations to patients in Brazil and is currently involved in multiple clinical studies and trials. Isodiol is acquiring 99% of PUR-Brazil.
The company will acquire BSPG for $12,500,000 USD to be paid out over 12 months and stock compensation in the amount of $37,000,000 USD based on the closing price on December 15, 2017. The stock issuance will be subject to a 36-month escrow leak out period. Additional milestone payments are anticipated to be paid and shall be disclosed upon the closing of this transaction. The milestones have been withheld to protect proprietary and intellectual property that are in final stages of development and implementation. The Company will not be assuming any debt as a part of this transaction. The closing of this transaction will happen on or before April 1, 2018 and is subject to further due-diligence by the Company.
All web properties of BSPG have been put on hiatus for the moment and will be released in the very near future. For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
$ISOLF News
VANCOUVER, British Columbia, Dec. 17, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has entered into a binding agreement to acquire the Biosynthesis Pharma Group (BSPG), an industry leading producer of industrial hemp, it’s derivatives and pharmaceutical compounds for use in the medicinal, nutraceutical, food and cosmetic industries.
Through BSPG’s industrial-sized, proprietary extraction methodologies, BSPG produces high-purity, bioactive cannabinoids that are used in pharmaceutical applications to benefit those suffering from a range of life-threatening and non-life-threatening illnesses. BSPG is currently conducting clinical trials involving its product through strategic partnerships around the globe.
“It has been a part of Isodiol’s growth strategy to aggressively pursue international expansion. Through this acquisition, the company is aligned to penetrate foreign markets particularly in the United Kingdom, Europe, Asia, South and Central America. We will broaden our product availability and make the most bioactive cannabinoid products available on a global scale. This acquisition puts us at the forefront of global cannabinoid clinical research and studies which will compliment our current efforts in Brazil and other markets we are presently developing,” said Marcos Agramont, CEO of Isodiol.
The BSPG acquisition includes multiple entities that are strategic to the future of Isodiol. Each of these entities are intended to have a distinct purpose within the Isodiol organization, whether it be defined by geography, applicable laws, or line of business. The entities include:
Biosynthesis Pharma Group Limited (BSPG-HK): organized in Hong Kong and maintains a correspondent office in the United Kingdom. Isodiol is acquiring 100% of BSPG-HK.
Trigal Pharma GmbH (TP-Austria): organized in Austria, TP-Austria’s business includes, but is not limited to, the handling of regulatory and governmental policies and supply of pharmaceutical-grade CBD to pharmacies in Europe. Isodiol is acquiring 100% of TP-Austria.
Hankang (Yunnan) Biotech Co., Ltd. (HBTC-China): organized in The People’s Republic of China, HBTC-China’s business includes, but is not limited to, operating a facility approved by the Chinese government to grow hemp as well as extract and export CBD globally. China is the world’s largest producer of hemp and is the largest supplier of raw hemp and fiber to the United States. Isodiol is acquiring 70% of HBTC-China.
BSPG Laboratories Limited (BSPGL-UK): organized in the United Kingdom, BSPGL-UK’s business includes, but is not limited to, operating a facility that refines the CBD molecule to a purity of 99.5% + that is pharmaceutical-grade, THC-Free and highly bioactive. Isodiol is acquiring 100% of BSPGL-UK.
Pure CBD Limited (PURE-UK): organized in the United Kingdom, PURE-UK supplies pharmaceutical products under the specials category with the approval of the National Health Service. Isodiol is acquiring 100% of PURE-UK.
Purodiol Limited (PUR-UK): organized in the United Kingdom, PUR-UK manufactures pharmaceutical products under the brand name Purodiol. Isodiol is acquiring 100% of PUR-UK.
Purodiol Do Brasil Ltda (PUR-Brazil): organized in Brazil, PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations to patients in Brazil and is currently involved in multiple clinical studies and trials. Isodiol is acquiring 99% of PUR-Brazil.
Hope your having a Great weekend Mick, I thought that you might find this news that just went out on $ISOLF 10 Minutes ago very interesting. It looks as though Isodiol has moved into the Big Leagues.
Here's $ISOLF News Below.
Isodiol International Inc. Announces Binding Agreement to Acquire Biosynthesis Pharma Group
December 17, 2017 19:15 ET | Source: Isodiol
VANCOUVER, British Columbia, Dec. 17, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has entered into a binding agreement to acquire the Biosynthesis Pharma Group (BSPG), an industry leading producer of industrial hemp, it’s derivatives and pharmaceutical compounds for use in the medicinal, nutraceutical, food and cosmetic industries.
Through BSPG’s industrial-sized, proprietary extraction methodologies, BSPG produces high-purity, bioactive cannabinoids that are used in pharmaceutical applications to benefit those suffering from a range of life-threatening and non-life-threatening illnesses. BSPG is currently conducting clinical trials involving its product through strategic partnerships around the globe.
“It has been a part of Isodiol’s growth strategy to aggressively pursue international expansion. Through this acquisition, the company is aligned to penetrate foreign markets particularly in the United Kingdom, Europe, Asia, South and Central America. We will broaden our product availability and make the most bioactive cannabinoid products available on a global scale. This acquisition puts us at the forefront of global cannabinoid clinical research and studies which will compliment our current efforts in Brazil and other markets we are presently developing,” said Marcos Agramont, CEO of Isodiol.
The BSPG acquisition includes multiple entities that are strategic to the future of Isodiol. Each of these entities are intended to have a distinct purpose within the Isodiol organization, whether it be defined by geography, applicable laws, or line of business. The entities include:
Biosynthesis Pharma Group Limited (BSPG-HK): organized in Hong Kong and maintains a correspondent office in the United Kingdom. Isodiol is acquiring 100% of BSPG-HK.
Trigal Pharma GmbH (TP-Austria): organized in Austria, TP-Austria’s business includes, but is not limited to, the handling of regulatory and governmental policies and supply of pharmaceutical-grade CBD to pharmacies in Europe. Isodiol is acquiring 100% of TP-Austria.
Hankang (Yunnan) Biotech Co., Ltd. (HBTC-China): organized in The People’s Republic of China, HBTC-China’s business includes, but is not limited to, operating a facility approved by the Chinese government to grow hemp as well as extract and export CBD globally. China is the world’s largest producer of hemp and is the largest supplier of raw hemp and fiber to the United States. Isodiol is acquiring 70% of HBTC-China.
BSPG Laboratories Limited (BSPGL-UK): organized in the United Kingdom, BSPGL-UK’s business includes, but is not limited to, operating a facility that refines the CBD molecule to a purity of 99.5% + that is pharmaceutical-grade, THC-Free and highly bioactive. Isodiol is acquiring 100% of BSPGL-UK.
Pure CBD Limited (PURE-UK): organized in the United Kingdom, PURE-UK supplies pharmaceutical products under the specials category with the approval of the National Health Service. Isodiol is acquiring 100% of PURE-UK.
Purodiol Limited (PUR-UK): organized in the United Kingdom, PUR-UK manufactures pharmaceutical products under the brand name Purodiol. Isodiol is acquiring 100% of PUR-UK.
Purodiol Do Brasil Ltda (PUR-Brazil): organized in Brazil, PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations to patients in Brazil and is currently involved in multiple clinical studies and trials. Isodiol is acquiring 99% of PUR-Brazil.
MADDSTACKER check out this news that $ISOLF just put out, they have officially moved into the Big Leagues with this news!
$ISOLF News Below, just went out 5 Minutes ago.
Isodiol International Inc. Announces Binding Agreement to Acquire Biosynthesis Pharma Group
SharePrint
December 17, 2017 19:15 ET | Source: Isodiol
VANCOUVER, British Columbia, Dec. 17, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has entered into a binding agreement to acquire the Biosynthesis Pharma Group (BSPG), an industry leading producer of industrial hemp, it’s derivatives and pharmaceutical compounds for use in the medicinal, nutraceutical, food and cosmetic industries.
Through BSPG’s industrial-sized, proprietary extraction methodologies, BSPG produces high-purity, bioactive cannabinoids that are used in pharmaceutical applications to benefit those suffering from a range of life-threatening and non-life-threatening illnesses. BSPG is currently conducting clinical trials involving its product through strategic partnerships around the globe.
“It has been a part of Isodiol’s growth strategy to aggressively pursue international expansion. Through this acquisition, the company is aligned to penetrate foreign markets particularly in the United Kingdom, Europe, Asia, South and Central America. We will broaden our product availability and make the most bioactive cannabinoid products available on a global scale. This acquisition puts us at the forefront of global cannabinoid clinical research and studies which will compliment our current efforts in Brazil and other markets we are presently developing,” said Marcos Agramont, CEO of Isodiol.
The BSPG acquisition includes multiple entities that are strategic to the future of Isodiol. Each of these entities are intended to have a distinct purpose within the Isodiol organization, whether it be defined by geography, applicable laws, or line of business. The entities include:
Biosynthesis Pharma Group Limited (BSPG-HK): organized in Hong Kong and maintains a correspondent office in the United Kingdom. Isodiol is acquiring 100% of BSPG-HK.
Trigal Pharma GmbH (TP-Austria): organized in Austria, TP-Austria’s business includes, but is not limited to, the handling of regulatory and governmental policies and supply of pharmaceutical-grade CBD to pharmacies in Europe. Isodiol is acquiring 100% of TP-Austria.
Hankang (Yunnan) Biotech Co., Ltd. (HBTC-China): organized in The People’s Republic of China, HBTC-China’s business includes, but is not limited to, operating a facility approved by the Chinese government to grow hemp as well as extract and export CBD globally. China is the world’s largest producer of hemp and is the largest supplier of raw hemp and fiber to the United States. Isodiol is acquiring 70% of HBTC-China.
BSPG Laboratories Limited (BSPGL-UK): organized in the United Kingdom, BSPGL-UK’s business includes, but is not limited to, operating a facility that refines the CBD molecule to a purity of 99.5% + that is pharmaceutical-grade, THC-Free and highly bioactive. Isodiol is acquiring 100% of BSPGL-UK.
Pure CBD Limited (PURE-UK): organized in the United Kingdom, PURE-UK supplies pharmaceutical products under the specials category with the approval of the National Health Service. Isodiol is acquiring 100% of PURE-UK.
Purodiol Limited (PUR-UK): organized in the United Kingdom, PUR-UK manufactures pharmaceutical products under the brand name Purodiol. Isodiol is acquiring 100% of PUR-UK.
Purodiol Do Brasil Ltda (PUR-Brazil): organized in Brazil, PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations to patients in Brazil and is currently involved in multiple clinical studies and trials. Isodiol is acquiring 99% of PUR-Brazil.
More Positive $ISOLF news
ISODIOL INTERNATIONAL ACQUIRES GLOBAL RIGHTS TO PRODUCE PRODUCTS UNDER AN INNOVATIVE DELIVERY SYSTEM PATENT
Isodiol International Inc.'s division, C3 Global Biosciences (C3GBS), has agreed in principle to acquire the rights to become the exclusive worldwide distributor of Advanced Brain Monitoring's (ABM) electroencephalogram (EEG) technology in the phytoceutical field, specifically the cannabis community.
For the last 15 years, ABM has challenged conventional thinking by developing innovative medical devices that provide superior patient experience, lower healthcare costs, and improved quality of care. With this versatile, state of the art wireless EEG system, interpretation of physiological signals across a wide variety of real-world applications are finally here. The EEG system will allow physicians and researchers real-time feedback on the effect of Cannabis products. The EEG device is reimbursable and has designated CPT codes for physicians to submit to health insurance companies.
Andrew Serafini, C3GBS President, says, "The need to fast-track and bring to market therapeutic novel compounds that possess great potential in human diseases have a need for an FDA-approved drug validation technology that should become mandatory. The cannabis industry lacks verification methodologies and C3GBS is excited to bring the EEG technology to the forefront to help further discover the benefits in real time. This will invariably result in evidence-based data gathering to help support and guide the healthcare practitioner."
"This is another monumental step taken by Isodiol and C3GBS to be the global leader in cannabis research, science, innovation, and technology to positively impact patient outcomes. The EEG system offers another diagnostic tool, that is FDA approved, to help understand how cannabis is beneficial to the human body," added Isodiol CEO, Marcos Agramont.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry, including commercialization of 99-per-cent-plus-pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations, and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs and expanding its phytoceutical portfolio, and it will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
$ISOLF News Just out!
Isodiol International Inc. Initiates Implementation of Blockchain Technology
VANCOUVER, British Columbia, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce the Company has initiated Phase 1 of implementing cryptocurrency through BitPay, a global blockchain payments technology platform.
Founded in 2011, BitPay has succeeded in making payments faster and more secure at a low cost, while making it easier for businesses to accept bitcoin payments. BitPay’s bitcoin payment experience is used by hundreds of thousands of users around the globe.
“The Isodiol customer experience is always a priority for us and accepting bitcoin seemed to be a natural implementation, as we want to ensure that our customers have choices as to how they shop and ultimately have the best experience possible,” said Marcos Agramont, CEO of Isodiol. “In Phase 2 of the implementation, which takes place in the first quarter of 2018, we anticipate cryptocurrency acceptance across all of Isodiol’s family of brands.”
For more information on Isodiol, please visit www.isodiol.com
For more information on BitPay, please visit www.bitpay.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Your right there is a great base forming now. Overall very positive day so far.
$ISOLF News just out.
VANCOUVER, British Columbia, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce Be Tru Organics™ has commenced the process of distributing product to Erewhon Natural Foods, a premier supermarket chain in California.
“We are always looking for new ways to expand our company’s reach and further diversify our product offerings,” said Marcos Agramont, CEO of Isodiol. “We closed the 100% acquisition of Be Tru last week, and in this short amount of time, we have already seen strong results from this partnership. This partnership will continue to open additional revenue streams, and enable Isodiol to penetrate the mainstream market and provide consumers with natural, high-quality, health and wellness products.”
Since the late 1960s, Erewhon has been committed to providing foods and products that change the lives of consumers. Erewhon sets the standard for the highest quality ingredients possible and endlessly works towards providing their consumers with the best foods and products the earth can offer.
“Be Tru is very pleased to share this update and we expect many more opportunities to present themselves in the coming months,” said Keith Gordon, CEO of Be Tru Organics. “As we move along in our partnership with Isodiol, we will begin to include their products in our distribution.”
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Tru Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont,CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
More News out on $ISOLF, it looks like they just closed another deal!
VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a definitive agreement with C3 Global Biosciences™ (C3GBS), a cause-driven organization committed to developing sustainable health solutions through the advancement of cannabis science.
This news is in connection with Isodiol’s previous announcement affirming that the Company had entered into a binding agreement with C3GBS. The official press release can be viewed here.
“At Isodiol, we believe that the ideation, creation, and evaluation of new ideas, is an interconnected process that drives innovation forward,” said Marcos Agramont, CEO of Isodiol. “C3GBS’s world-class team has a clear mission, focused strategy and healthy culture – all of which we expect will support the creation of value over the long term for Isodiol, our shareholders, and society.”
C3GBS’ strategy involves using science and technology-based innovation to deliver better patient outcomes in areas of healthcare with the utmost need. With C3GBS, Isodiol seeks to develop and advance proprietary, pharmaceutical-grade CBD Bioactive products that can produce positive real-world outcomes for patients and healthcare providers.
“C3GBS is an expert in conducting research, turning insights into tangible products, and incorporating those products into treatment programs, which are then evaluated with academic rigor,” said Agramont. “They are well-prepared for a world with both a growing and aging population that has evolving healthcare needs.”
$ISOLF News just out!
VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has finalized the definitive agreement to acquire 100% of Be Tru Organics™, a cause driven organization specializing in holistic products for everyday health and balance in the human body with the goal to promote well-being within the mind, body, & soul.
This news is in connection with Isodiol’s previous announcement confirming the Company had entered into a binding agreement with Be Tru Organics. The press release can be viewed here.
“The acquisition with Be Tru Organics is yet another major milestone for Isodiol and we are very pleased to have been able to finalize this partnership so quickly,” said Marcos Agramont, CEO of Isodiol. “Not only does this partnership add diversity to the Isodiol’s already strong portfolio of products, but gives the Company access to the mainstream distribution channels that Be Tru Organics has been able to penetrate.”
There have been no changes to the terms of this agreement. Isodiol will issue Be Tru Organics $2,000,000 USD in stock, subject to a 36-month escrow.
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Tru Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Its not exactly the smartest business move to give away your trade secret to your competition IMHO.
Here's a better article on Isodiol's Hops Products.
https://www.google.ca/amp/s/www.civilized.life/articles/scientists-have-developed-a-non-cannabis-cbd-product-made-out-of-hops/amp.html
Positive update on $ISOLF
ORIGINAL: Isodiol International Inc. to Present, Exhibit at 25th Annual American Academy of Anti-aging Medicine World Congress
2017-12-07 11:00 ET - News Release
LAS VEGAS, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Dr. Ronald Aung-Din, Medical, Science and Development Advisor at Isodiol, will present at the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress being held at the Venetian/Palazzo Resort in Las Vegas, December 14-16.
Dr. Aung-Din, a board-certified neurologist with more than 35 years of experience in general neurology and neuro-psychiatry, will take the stage to discuss how Direct Effects Technology™ has refashioned the application of CBD for those suffering from conditions such as Parkinson’s disease, peripheral neuropathy and cluster headaches. Direct Effects is a patented non-systemic delivery system utilized in Isodiol’s IsoDerm Direct Effects Cream. The topical is applied to the back of the neck at the hairline, where it is picked up by the free nerve endings located in the dermis of the skin for a highly effective delivery of the compound.
“We have long been working with neurologists and physicians in Brazil to bring relief to patients using this technology and look forward to having our newly appointed advisor, Dr. Aung-Din, share the science behind Direct Effects with A4M attendees,” said Marcos Agramont, CEO of Isodiol. “Direct Effects has made IsoDerm more effective for those suffering from neurological, psychiatric, and physical pain. We plan to develop further products utilizing the Direct Effects delivery method.”
The speaking engagement follows Isodiol’s announcement that the company has acquired the global rights for the patented Direct Effects Technology. The licensing rights apply to IsoDerm, as well as five other propriety pharmaceutical compounds to be delivered by the Direct Effects system. The official press release can be viewed here.
IsoDerm Direct Effects Cream, along with Isodiol’s diverse product line which includes non-cannabis CBD tablets, transdermal patches, and CBD-infused beverages, will be exhibited during the event at BOOTH 4085.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
$ISOLF News out!
VANCOUVER, British Columbia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a Binding Agreement to acquire 25% of Canadian National Pharma Group Inc., a pharmaceutical manufacturing company which is currently in the final stages of receiving its Licensed Dealer (“LD”) status under the provisions of the Canadian Controlled Drugs and Substances Act, in order to commence production of cannabis and hemp extracts or isolate. The agreement, which entails complete exclusivity to Isodiol for use of the license and facility, includes an option which provides Isodiol with rights of first refusal in future offerings, and to expand its ownership in CN Pharma to an overall controlling interest.
CN Pharma has completed the build of a Health Canada compliant facility according to the highest standards for Health Canada’s final inspection, with more than 9,750 sq.ft of usable space, located in the city of Abbotsford, BC. Within this facility, the company will be able to process and manufacture controlled substances, including cannabis and hemp, with the ability to expand the footprint if necessary.
Licensed Dealers approved by Health Canada have the right to handle all cannabis derivatives, import and export oils and isolates, prepare various formulation and mixtures, participate in research or testing activities, and conduct new product and drug development.
“As a supplier of raw materials and active pharmaceutical ingredients, our company prides itself on its quality and standards, supplier selection process, audits, and inspections,” said Marcus Dahl, President and CEO of CN Pharma. “We strongly believe this partnership will help elevate CN Pharma to new levels through additional capital investments into our infrastructure growth and expansion of facilities, equipment, and services.”
Marcos Agramont, CEO of Isodiol, said, “With this acquisition, we will continue to position Isodiol as a global provider of pharmaceutical grade phytoceuticals, by developing high quality bioactive products within many different verticals such as personal care products, beverages and edibles, topicals, nutraceutical supplements, and capsules. Our roadmap in Canada includes further vertical integration from growth to extraction, as well as the processing and manufacturing of goods.”
$ISOLF www.isodiol.com
Have a great week everybody.
No problem mick, have yourself a great Sunday. Cheers
Good morning PistolPete, hope your having a great weekend. I'm not sure if you are following $ISOLF as of yet but here's their news from Friday. $ISOLF has had an amazing November, just thought i'd bring it to your attention. Cheers
Isodiol International Inc. Signs Binding Agreement to Acquire 100% Stake in Be Tru Organics™
PRESS RELEASE GlobeNewswire
Dec. 1, 2017, 03:21 PM
VANCOUVER, B.C., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a binding agreement to acquire 100% stake in Be Tru Organics™, a cause driven organization specializing in holistic products for everyday health and balance in the human body with the goal to promote well-being within the mind, body, & soul.
Be Tru is a formulator, marketer, and seller of a proprietary line of hemp extract products. Their offerings, which include topicals, oral sprays and edibles, contain powerful blends of more than 75 organic botanical terpenes and sold under the company’s Be Tru Organics™, Canatru™, and Cebatru™ brands.
“Isodiol and Be Tru share the common goal of providing consumers with high-quality products that promote physical and mental well-being,” said Marcos Agramont, CEO of Isodiol. “This strategic partnership would further enable us to diversify our product offerings, thus generating additional revenue streams. With both companies committed to being at the forefront of product innovation, this acquisition was an easy decision for us.”
Keith Gordon, CEO of Be Tru Organics, stated, “After our first discussion with Isodiol, it was a no-brainer that this partnership would not only be beneficial to both companies, but significantly strengthen our brands to benefit customers. We look forward to scaling our business and connecting with a group of global consumers that otherwise would have been inaccessible.”
As part of this agreement, Isodiol will issue Be Tru Organics™ up to $2,000,000 USD in stock, which will be payable at closing with shares of Isodiol’s common stock, valued at the closing price. This stock will be subject to a 36-month escrow as part of this agreement and anticipated to close within 30 days.
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Tru Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont,CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Here is $ISOLF's News from Friday afternoon.
Isodiol International Inc. Signs Binding Agreement to Acquire 100% Stake in Be Tru Organics™
PRESS RELEASE GlobeNewswire
Dec. 1, 2017, 03:21 PM
VANCOUVER, B.C., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a binding agreement to acquire 100% stake in Be Tru Organics™, a cause driven organization specializing in holistic products for everyday health and balance in the human body with the goal to promote well-being within the mind, body, & soul.
Be Tru is a formulator, marketer, and seller of a proprietary line of hemp extract products. Their offerings, which include topicals, oral sprays and edibles, contain powerful blends of more than 75 organic botanical terpenes and sold under the company’s Be Tru Organics™, Canatru™, and Cebatru™ brands.
“Isodiol and Be Tru share the common goal of providing consumers with high-quality products that promote physical and mental well-being,” said Marcos Agramont, CEO of Isodiol. “This strategic partnership would further enable us to diversify our product offerings, thus generating additional revenue streams. With both companies committed to being at the forefront of product innovation, this acquisition was an easy decision for us.”
Keith Gordon, CEO of Be Tru Organics, stated, “After our first discussion with Isodiol, it was a no-brainer that this partnership would not only be beneficial to both companies, but significantly strengthen our brands to benefit customers. We look forward to scaling our business and connecting with a group of global consumers that otherwise would have been inaccessible.”
As part of this agreement, Isodiol will issue Be Tru Organics™ up to $2,000,000 USD in stock, which will be payable at closing with shares of Isodiol’s common stock, valued at the closing price. This stock will be subject to a 36-month escrow as part of this agreement and anticipated to close within 30 days.
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Tru Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont,CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Check it out MADDSTACKER more news just went out on $ISOLF 10 minutes ago.
VANCOUVER, B.C., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a binding agreement to acquire 100% stake in Be Tru Organics™, a cause driven organization specializing in holistic products for everyday health and balance in the human body with the goal to promote well-being within the mind, body, & soul.
Be Tru is a formulator, marketer, and seller of a proprietary line of hemp extract products. Their offerings, which include topicals, oral sprays and edibles, contain powerful blends of more than 75 organic botanical terpenes and sold under the company’s Be Tru Organics™, Canatru™, and Cebatru™ brands.
“Isodiol and Be Tru share the common goal of providing consumers with high-quality products that promote physical and mental well-being,” said Marcos Agramont, CEO of Isodiol. “This strategic partnership would further enable us to diversify our product offerings, thus generating additional revenue streams. With both companies committed to being at the forefront of product innovation, this acquisition was an easy decision for us.”
Keith Gordon, CEO of Be Tru Organics, stated, “After our first discussion with Isodiol, it was a no-brainer that this partnership would not only be beneficial to both companies, but significantly strengthen our brands to benefit customers. We look forward to scaling our business and connecting with a group of global consumers that otherwise would have been inaccessible.”
As part of this agreement, Isodiol will issue Be Tru Organics™ up to $2,000,000 USD in stock, which will be payable at closing with shares of Isodiol’s common stock, valued at the closing price. This stock will be subject to a 36-month escrow as part of this agreement and anticipated to close within 30 days.
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Tru Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
More news just went out on $ISOLF
ISODIOL INTERNATIONAL INC. ANNOUNCES APPOINTMENT OF DR. RONALD AUNG-DIN AS AN ADVISOR, CLOSES STRATEGIC FINANCING
Isodiol International Inc. has appointed Dr. Ronald Aung-Din as a medical, science and development adviser to the company.
Dr. Aung-Din, a board-certified neurologist with more than 25 years of practice in general neurology and neuro-psychiatry, joins Isodiol after pioneering significant scientific advancements in the medical community. During his tenure, Dr. Aung-Din participated in more than 60 pharmaceutical-sponsored studies that proved to be instrumental in the development of numerous drugs for utilization and treatment of degenerative and neurological conditions.
In this role, Dr. Aung-Din will aid in the development of a series of new products designed to have a profound impact on the daily lives of those suffering from symptoms of peripheral neuropathy, cluster headaches, migraines, Parkinson's disease, multiple sclerosis, and other debilitating conditions.
"We are excited to welcome Dr. Ronald Aung-Din to Isodiol and are confident that he will be a valuable addition to the team," said Marcos Agramont, CEO of Isodiol. "We have been working with neurologists and physicians in Brazil to bring relief to patients and have already seen tremendous success with our efforts. This is expected to not only continue, but strengthen with the expertise of Dr. Aung Din."
Dr. Aung-Din has also patented several other drug delivery systems that are currently being utilized today. It is with Dr. Aung-Din's patented Direct Effects Topical Delivery System that the Company is currently delivering its proprietary cannabidiol under the brand name IsoDerm. IsoDerm has recently been approved by National Health Surveillance Agency of Brazil (ANVISA) and is listed on Brazil's special category list allowing physicians to be able to prescribe this product for their patients. Isodiol has licensed these products and formulations that Dr. Aung-Din has developed and will commence further development and ultimate distribution on a global basis. Details of this agreement can be read here.
Isodiol has also completed an additional round of financing. The intent of the raise is to fund recent acquisitions and allow the company to remain flexible in M&A transactions and future international expansion. The Company raised a total of $9,016,000.00 CAD by issuing 12,183,783 units at $.74 with a full three-year warrant at $.75. All financing units are subject to a four (4) month hold period.
The round was led by Serruya Private Equity, a family-managed private equity group with a heritage of developing brands and participating in such global opportunities.
"The Serruya family is pleased to participate in a material way in this recent round of financing by Isodiol," stated Aaron Nathaniel Serruya. "As we have seen with our sponsorship of Aphria and others in this space, those companies with exceptional leadership and intellectual property will thrive in this industry and we believe that Isodiol has both of these components."
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
This news went out Friday afternoon on $ISOLF
ISODIOL INTERNATIONAL INC. SIGNS BINDING AGREEMENT TO ACQUIRE 100% OF C3 GLOBAL BIOSCIENCES
Isodiol International Inc. has entered into a binding agreement to acquire 100 per cent of C3 Global Biosciences (C3GBS), a cause-driven organization committed to developing sustainable health solutions through the advancement of cannabis science.
"Isodiol and C3GBS are truly complementary. We look forward to bringing the C3GBS brand and world-class team on board to pursue the shared vision of providing consumers with the highest quality of bioactive CBD [cannabidiol] products," said Marcos Agramont, chief executive officer of Isodiol. "By combining the two companies, we can align our efforts strategically to further strengthen our portfolio of assets. This partnership will be aimed at increasing market expertise as we establish both companies as leaders in the CBD market."
C3GBS's mission is to be the global leader in CBD research, science, innovation and technology to impact consumer lives resulting in markedly improved patient outcomes through sound clinical studies and evidence-based empirical data gathered by validated devices and platforms. It is passionately driven to continue the research and development of CBD and other cannabinoids to improve the quality of life for athletes on and off the field.
C3GBS is proud to partner with and support the mission of Athletes for Care and play a key role in creating a community where athletes can find support, opportunity and purpose in life after a career in sports.
Dr. H.J. Raza, chief medical officer for C3GBS, will join the team as a member of Isodiol's medical advisory board, where he will provide insight, scientific direction and expertise to the company. Dr. Raza, an internationally respected physician, researcher and educator, brings with him more than 25 years of professional experience. Dr. Raza completed his medical education (MD) and neuroscience research (PhD) at the Mount Sinai School of Medicine, with training and board certification in internal medicine at the NYU Medical Center.
News just out on $ISOLF
$ISOLF Signs Binding Agreement to Acquire 100% of C3 Global Biosciences,
VANCOUVER, British Columbia, Nov. 24, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a binding agreement to acquire 100% of C3 Global Biosciences (C3GBS), a cause driven organization committed to developing sustainable health solutions through the advancement of cannabis science.
“Isodiol and C3GBS are truly complementary. We look forward to bringing the C3GBS brand and world class team onboard to pursue the shared vision of providing consumers with the highest quality of bioactive CBD products,” said Marcos Agramont, CEO of Isodiol. “By combining the two companies, we can align our efforts strategically to further strengthen our portfolio of assets. This partnership will be aimed at increasing market expertise as we establish both companies as leaders in the CBD market.”
C3GBS’ mission is to be the global leader in CBD research, science, innovation and technology to impact consumer lives resulting in markedly improved patient outcomes through sound clinical studies and evidence-based empirical data gathered by validated devices and platforms. They are passionately driven to continue the research and development of CBD and other cannabinoids to improve the quality of life for athletes on and off the field.
C3GBS is proud to partner with and support the mission of Athletes for Care and play a key role in creating a community where athletes can find support, opportunity and purpose in life after a career in sports.
Dr. HJ Raza, Chief Medical Officer for C3GBS, will join the team as a member of Isodiol’s Medical Advisory Board where he will provide insight, scientific direction, and expertise to the Company. Dr. Raza, an internationally respected physician, researcher, and educator, brings with him more than 25 years of professional experience. Dr. Raza completed his medical education (MD) and neuroscience research (PhD) at The Mount Sinai School of Medicine, with training and board certification in Internal Medicine at The NYU Medical Center.
As part of this agreement, Isodiol will issue C3GBS up to $1,000,000 USD in stock subject to a 36-month escrow as part of this agreement.
For more information on Isodiol, please visit www.isodiol.com
For more information on C3 Global Bioscience, please visit www.c3globalbiosciences.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
$ISOLF Barchart 100% http://bit.ly/2BjGWVm http://www.isodiol.com
$ISOLF will be on BNN http://www.bnn.ca/
Dec 4, 11:40am Easter Time
$ISOLF News
ISODIOL INTERNATIONAL INC. SIGNS DEFINITIVE AGREEMENT TO ACQUIRE BRADLEY'S BIOSCIENCE INC., AND CLOSES STRATEGIC FINANCING
Isodiol International Inc. has entered into a definitive agreement in connection with its previously announced letter of intent to acquire Bradley's Bioscience Inc., a leading manufacturer and distributer of hemp oil and nicotine e-liquids.
"The acquisition of Bradley's Bioscience, a market poised to be a $61.4-billion industry by 2025 is another major milestone for the company," said Marcos Agramont, chief executive officer of Isodiol. "Not only does this allow the company to penetrate a new market, but we are now also able to provide consumers with a safer alternative to smoking. Over all, we believe Bradley's Bioscience is a perfect fit with Isodiol and our long-term vision and we are very pleased to be moving forward with this agreement."
$ISOLF
Amazing Article on ISOL on CNBC
https://www.cnbc.com/2017/11/09/globe-newswire-isodiol-international-inc-signs-letter-of-intent-to-acquire-bradleyas-bioscience-inc-expands-into-vaping-and-thc-additive.html
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=27007773#BHmHjF1yhZJsctzJ.99
$ISOLF
Isodiol International Inc. Upgrades to OTCQB
VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Isodiol’s common shares have been approved for trading on the OTCQB Venture Market in the United States. The trading symbol will remain as ISOLF.
The OTCQB is the ideal exchange for emerging companies. To be eligible for the OTCQB, companies must be up to date in reporting with the U.S. Securities Exchange Commission, meet a minimum price bid test, and undergo an annual verification and management certification process. These standards and regulations will provide investors with confidence and enhance their trading experiences.
“We are very pleased with this OTCQB listing. Listing on the OTCQB is part of Isodiol’s overall strategy to increase awareness to international investors,” said Marcos Agramont, CEO of Isodiol. “This listing will provide the Company with a significant trading platform for international shareholders and future investors, while making the Company itself easily available to American investors.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
78 Cents Up in Canada now. $ISOLF
$ISOLF https://isodiol.com/
Isodiol International Inc. (ISOL.CN)
0.640 +0.110 (+20.75%) 11/17/17 [CNSX]
BARCHART OPINION for Fri, Nov 17th, 2017
Set Alerts Watchlist
Overall Average:
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
One last thing, for those of you who haven't seen this video as of yet I recommend if you have a few minutes to watch it. If you have questions about the company and want to have a better idea of their long term game plan then this video is a must watch IMHO.
$ISOLF https://isodiol.com/
Isodiol International Inc. (ISOL.CN)
0.640 +0.110 (+20.75%) 11/17/17 [CNSX]
BARCHART OPINION for Fri, Nov 17th, 2017
Set Alerts Watchlist
Overall Average:
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
One last thing, for those of you who haven't seen this video as of yet I recommend if you have a few minutes to watch it. If you have questions about the company and want to have a better idea of their long term game plan then this video is a must watch IMHO.
Here's a video from $ISOLF that explains the future direction of the company. If your new to $ISOLF then watching this video will be very helpful IMHO.
$ISOLF is based out of Carlsbad, California.
Fact. California’s population of 39.2 million is 45% larger than its 6 nearest MJ states combined, with an aggregate number of residence in Alaska, Arizona, Colorado, Nevada, Oregon and Washington equaling 27.3 million. Simply put, California’s population is absolutely massive. And that population will be, unequivocally, the driving force in the cannabis movement throughout the US.
The $5 billion market. Let’s compare California with Colorado. California is approximately seven times larger in population than Colorado. In addition, tourism in California in 2016 exceeded 251 million visitors, and in Colorado it was approximately 82 million. Similar to California, Colorado was a medicinal cannabis state when in 2014 it ushered in Adult-Use (a/k/a “recreational”) cannabis sales to the general public. California has been a medicinal cannabis state since 1996 and in less than 60 days will usher in Adult-Use cannabis. In 2016 California sales of medicinal cannabis were approximately $2.7 billion and are expected to be approximately $3.6 billion in 2017. Colorado total sales (medicinal and Adult-Use) in 2016 were approximately $1.2 billion, and reports state that within the first ten months of 2017 Colorado has already surpassed the $1 billion sales mark. If we use the above variables (population, tourism, commencement of Adult-Use cannabis), it’s highly probable in 2018 California will exceed $5 billion in cannabis sales.
Rules, Regulations & Licenses. There is no empirical data available that provides accurate statistics on the number of nurseries, growers, manufactures and dispensaries of cannabis-related products in California. But a “back of the napkin” approach is that at least 70% and probably closer to 90% of the growers, manufacturers, and dispensaries in California will either not be properly licensed in the next 60 days, or will not be able to provide clear “chain of title” relating to the cannabis sold. This is a state requirement that is anticipated to be strongly enforced by the State of California as it implements “Track & Trace”, a methodology that allows the state to follow all cannabis products from the seed, through manufacturing, to the dispensary.
Quality Above All Else. The current shortage of cannabis production in California that is capable of passing laboratory testing, a 2018 state requirement in order to sell to dispensaries, is staggering. According to the Los Angeles Times more than 80% of sampled cannabis grown in California was contaminated with pesticides, fungicides and/or infestation. Consequently, the majority of cannabis grown in California would not pass the proposed 2018 safe levels of purity.
The Big Short(age). It now boils down to simply economics. The demand for cannabis in California in 2018 is expected to increase by about 50% from 2017, and the number of properly licensed cannabis growers and sellers will decrease by at least the same percentage. Unlike any other time in California’s history, the State of California will be regulating all things Cannabis. The State of California is notorious for getting what it wants – and starting in 2018 it wants cannabis tax revenue.
I just thought that I would bring $ISOLF to everyone's attention. Over the last several days there has been a significant spike in the volume.
www.isodiol.com
Here's a write up that went out Friday night on $ISOLF.
https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
Hope your doing well Pete, I thought you might find this company of interest. There's been a big spike in Volume over the last few days.
$ISOLF www.isodiol.com
Check out this article that just went out Friday night on the company.
https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
$ISOLF
Check this out MADDSTACKER this was written up last night from Barchart Opinion. Here's the link https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
Isodiol International Inc. (ISOL.CN)
0.640 +0.110 (+20.75%) 11/17/17 [CNSX]
BARCHART OPINION for Fri, Nov 17th, 2017
Set Alerts Watchlist
Overall Average:
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
https://www.barchart.com/stocks/quotes/ISOL.CN/opinion